AddLife AB (publ) (ADDLF) Q1 2026 Earnings Call Transcript
AddLife AB reported strong financial performance in Q1 2026, maintaining high EBITA margins of 12.5% group-wide, with Labtech and Medtech divisions performing solidly. Organic growth reached 3% on a group level, excluding the divested U.K. endoscopy business, supported by resilient underlying demand. The company increased acquisition activity and highlighted a strong finish to 2025, with improving demand trends toward the end of the quarter. A video presentation from subsidiary BonsaiLab was featured post-call.
- ▪AddLife AB's Q1 2026 EBITA margin was 12.5%, slightly below the prior year's high but still robust.
- ▪Labtech achieved a 13.1% EBITA margin, up 1 percentage point year-over-year, while Medtech held near 13%.
- ▪Organic growth was 3% at the group level, excluding the divested U.K. endoscopy business.
- ▪Demand started cautiously but improved toward the end of the quarter, following a strong close to 2025.
- ▪The earnings call included a featured video from BonsaiLab, one of AddLife’s subsidiaries.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895387-addlife-ab-publ-addlf-q1-2026-earnings-call-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha